FEATURED CONTENT

• A New Mindset For Combination Product Development

  As we balance the time-to-market and risk for novel therapies, we must anticipate changing needs for combination device development, highlighting the technological paradigm shift.

• Sustainability Considerations For Drug Delivery Device End-To-End Solutions

  Learn how to address the gradual unlinking of economic activity from the consumption of finite resources and the removal of waste to support and help prevent a global climate catastrophe.

• Accelerating Novel Therapies To The Market

  The formulations for novel therapeutics require flexibility to support adaptive sterile manufacturing and an integrated approach for a path from development, to small batch manufacturing, to commercialization.

• Computational Modeling Of Injection-Related Tissue Responses

  Optimizing delivery along with the formulation is the key to successful clinical outcomes. Research is necessary to understand the relationship between body morphology, injection force, and needle length.

• High Viscosity Formulations: Developing A 'Human Solution' To Autoinjector Design

  Delivering high viscosity (HV) formulations with a truly human solution involves a balance between safety and practicality. Learn the importance of achieving this solution with HV autoinjector design.

• Characterization & Delivery Of Ultra-Viscous & Non-Newtonian Formulations

  Discover how to identify characteristics at the earliest stage, a vital step in autoinjector device platform development, with the use of the innovative Injection Characterization System (ICS).

• Patient-Centricity: The Importance Of Human Factors In The Pandemic Era

  Discover how patient-centricity is at the heart of drug delivery device design and innovation and how the global pandemic has highlighted the importance of patient-centric development in this field.

• Integrating Design And Industrialization To Optimize Cost, Quality & Time

  Explore how integrating design and industrialization teams can optimize the cost, quality, and time of developing a novel drug delivery system.

• Meeting The Challenge Of Delivering High-Volume Biologic Therapies

  As the industry moves toward self-administration to reduce healthcare costs and improve patient convenience, there is a compelling need for simple-to-use, low-cost, disposable devices.

• High Viscosity Formulations: Developing An Effective Primary Drug Container System

  The past few years have seen a significant increase in the number of high viscosity (HV) formulations (100 – 1000 cP) being developed. There are a number of steps that autoinjector developers can take to meet the challenges posed by such formulations. This white paper focuses on some of the techniques used to develop the ArQ™-Bios high viscosity platform.

• Choosing A CMO: Find The Best Match By Asking The Right Questions

  When selecting a CMO, it’s important to look at organizational alignment, senior leadership engagement, program management, commitment to projects large and small, and processes in place to manage risk. 

• Insights Into Drug Delivery Device Manufacturing From Development Through Commercialization

  Biologics and other targeted therapy techniques are creating opportunities for innovative device solutions that meet the needs of specific patient groups. As these therapies often require low annual volumes, the associated device manufacturing strategy must also fit commercial expectations, even at those volumes. 

• Keys To Driving Consistent Quality In Contract Manufacturing

  Complex products and supply chains present plenty of opportunities for failure, especially when new products are being developed and launched. This article discusses key ingredients to robust and advanced quality planning that are essential to quality in contract manufacturing.

• How To Design Autoinjectors For Highly Viscous Formulations

  The design of autoinjectors for increasingly viscous, high-volume drug requirements presents challenges in today’s pharma market. New materials offer opportunities to overcome these challenges. 

• 'Smart Devices' vs. 'Smart Design' In User-Centric Autoinjector Design

  Oval Medical has developed a novel Prefilled Primary Drug Container that resolves many drug compatibility and functionality issues associated with the use of traditional glass syringe and rubber plunger technologies.

• Improved Autoinjector Design Integrates Cyclic Olefin Syringe

  Oval Medical has developed a novel Prefilled Primary Drug Container that resolves many compatibility and functionality issues associated with traditional glass syringe and rubber plunger technologies.

• Drug Characterization: Key To Autoinjector Design For Challenging Formulations

  This article discusses the process used for the delivery of challenging formulations through understanding their properties and the challenges they pose at the very earliest stage in the design process.

• Using Polymeric PDC Technology To Improve Auto-Injector Design

  The limitations of using glass-based auto-injectors, such as contamination, and the need for delivering complex, viscous preparations, have led to a new approach that uses polymeric PDC technology instead. This article takes a look at what polymeric PDCs can offer in making auto-injectors truly patient-centric.

• Combining Human Needs With High Viscosity Formulations

  Explore the requirements of designing an autoinjector capable of handling the high pressures necessary for the delivery of highly viscous drug formulations with minimal impact on the patient.